Skip to main content
. 2023 May 15;24(10):8789. doi: 10.3390/ijms24108789

Figure 12.

Figure 12

A summary of the remarkable potentials of CHA-12 to combat SARS-CoV-2 infection as well as to reduce the pulmonary complications of COVID-19. The excellent relaxant effects of CHA-12 on pulmonary smooth muscle through antagonistic activity on CysLT1 (proven in vivo and in vitro), along with the prediction of remarkable effects on all host-based and SARS-CoV-2 3CLpro and PLpro targets, promise the discovery of a unique compound with high potential for the treatment of COVID-19.